**SR proteins and the nonsense-mediated decay mechanism are involved in human GLB1 gene alternative splicing**

Raúl Santamaria1,2,3, Lluïsa Vilageliu†1,2,3 and Daniel Grinberg*†1,2,3

Address: 1Departament de Genètica, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain, 2CIBER de Enfermedades Raras (CIBERER), Barcelona, Spain and 3Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain

Email: Raúl Santamaria - rsantame@hotmail.com; Lluïsa Vilageliu - lvilageliu@ub.edu; Daniel Grinberg* - dgrinberg@ub.edu

* Corresponding author †Equal contributors

**Abstract**

**Background:** The human GLB1 gene is known to give rise to two alternatively spliced mRNAs, which encode two different proteins: lysosomal β-galactosidase (β-gal) and elastin-binding protein (EBP). The β-gal transcript includes the 16 exons of the GLB1 gene. In the EBP transcript, exons 3, 4 and 6 are skipped, while exon 5 has a different reading frame. However, little is known on how this alternative splicing is regulated.

**Findings:** Cycloheximide treatment of HeLa cells and human fibroblasts revealed the presence of new transcripts that are otherwise degraded by nonsense-mediated decay (NMD). A minigene carrying the exons involved in the alternative splicing of GLB1 was constructed. Improving the acceptor-site scores of exons 3 or 4 increased the relative inclusion of these exons, but did not stop them being skipped in some transcripts. Overexpression of different SR proteins altered the relative proportion of the different transcripts produced by the minigene, indicating a possible mechanism for the regulation of the alternative splicing of GLB1. Finally, a comparison of this gene among different species was performed.

**Conclusion:** In the processing of the GLB1 RNA several transcripts are generated, but only those with a correct reading frame are not degraded. The differential inclusion/exclusion of exons could be partially explained by the relatively weak splice sites in the exons involved. Different SR proteins have an effect on the process of skipping of these exons, at least in the minigene conditions, indicating a possible mechanism for the regulation of the alternative splicing of the GLB1 gene.

**Background**

The existence of splicing in eukaryotic RNAs has been known for more than 25 years [1,2]. Alternative splicing, which may affect 30 to 70% of the genes in higher eukaryotes [3,4], allows the generation of multiple transcripts by different mechanisms such as exon skipping/inclusion, alternative 5' or 3' splice sites, intron retention or mutually exclusive exons. Alternative exons often have suboptimal splice sites and/or suboptimal length when compared with constitutive exons. Besides the proteins that are present in constitutive splicing, a group of proteins that bind to pre-mRNA sequences are also necessary in alternative splicing [5]. The sequences where these proteins bind are called exonic or intronic enhancers (ESEs or ISEs) and silencers (ESSs or ISSs). Most of the ESEs are recognized by SR proteins. They constitute a family of proteins that has an RS domain (rich in arginines and serines) and 1 or 2 RRM domains (RNA-binding domains) and are essential,
multifunctional splicing factors required both for spliceosome assembly and for alternative splicing [6]. On the other hand, the best characterized ESSs and ISSs are recognized by members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family, which are highly abundant RNA-binding proteins that lack an RS domain [7]. It is known that these proteins have a dose-dependent effect and that the binding of SR and hnRNP proteins on the pre-mRNA allows the splicing machinery to act in a tissue or in a developmental stage specific manner [8].

Nonsense-mediated mRNA decay (NMD) is a well known mechanism that degrades mRNAs harbouring premature termination nonsense codons (PTCs), not only generated by de novo nonsense mutations but also of those naturally found in physiological transcripts [9]. Over recent years, the coupling between NMD and alternative splicing has become more evident [10].

The GLB1 gene (GenBank NM_000404.1) located on chromosome 3 at 3p21.33 and organized into 16 exons, is the gene coding for the β-galactosidase protein (E.C.3.2.1.23) [11]. This enzyme cleaves terminal β-galactosides from different substrates in the lysosome. A second transcript generated by alternative splicing was described [12], but it was until 10 years later that the protein coded by this second transcript, the elastin-binding protein (EBP), was identified [13]. While the β-galactosidase cDNA is 2.5 kb long, the second transcript is only 2 kb, lacks exons 3, 4 and 6, and bears exon 5 in a different reading frame. The amount of the 2-kb transcript was also reported to be much lower (less than 1/10) than that of the 2.5-kb transcript [12].

Mutations in the GLB1 gene that result in the absence or reduced activity of the lysosomal enzyme β-galactosidase produce two different diseases: GM1-gangliosidosis (MIM# 230500) and Morquio B (MIM# 253010). A role of EBP in these diseases has also been suggested but is still under discussion [14,15].

Efforts have been made to establish the function and interactions of both proteins. In contrast, no studies have been reported on the way alternative splicing of the GLB1 gene is regulated. Here we present an attempt to establish the mechanisms underlying this alternative splicing.

Methods
Vector construction, cell culture and transfection conditions, and molecular biology techniques are provided [see Additional file 1].

Endogenous transcript analysis
After treating cells with cycloheximide (CHX), besides the β-Gal and EBP transcripts, other transcripts bearing different combinations of exons 3, 4 and 6 were found. If these transcripts were generated, they would bear PTCs, because they would produce new reading frames (Figure 1a). RT-PCR using an EBP-specific primer (Table 1) revealed the presence of these intermediate transcripts in the CHX-treated cells, as shown in Figure 1b and 1c. The experiment was also performed on human control fibroblasts to rule out a possible specific effect of the transformed HeLa cell line. Again, bands corresponding to the intermediate transcripts were observed, although their relative abundance was different between the two cell types (Figure 1b, c). Two primers that should not anneal to any of the two natural transcripts were designed (2_4F and 4_6F). RT-PCR using the 2_4F/C3R or the 4_6F/C3R primers on cDNA from CHX-treated and untreated HeLa cells displayed a band only in the CHX-treated cells (data not shown).

Minigene transcript analysis
In order to study GLB1 alternative splicing, a minigene (BX) including the alternatively spliced region of the gene (exons 2, 3, 4, 5, 6 and 7) was constructed (Figure 2a). The BX minigene was made so that the different combination of exons generated transcripts without PTCs. This allowed us to completely discard the effect of NMD as the cause of the observed pattern of bands.

To determine whether some of the missing intronic sequences were essential for the correct splicing of any of the cloned exons, the BX construct was transfected in HeLa cells and RT-PCR was carried out using plasmid-specific primers (T7/SP6). A single band was obtained (data not shown). Sequencing of this PCR product showed that it corresponded to a transcript that included the 6 cloned exons, indicating that the intron regions present in the BX construct bore the necessary cis sequences for correct splicing. If alternative splicing giving rise to the EBP transcript was taking place, it was at a very low level (as in the endogenous splicing), since no band corresponding to this transcript was detected.

In order to check whether EBP-specific splicing occurred at all, RT-PCR was performed with EBP-specific primers. Both T7/EBPR and EBPF/SP6 pairs of primers produced a PCR band corresponding to the EBP transcript. However, the band corresponding to the EBP transcript was a minor one and extra bands, corresponding to other intermediate transcripts, were also observed. The BX lane in Figure 3a shows the results for the T7/EBPR pair of primers. Similar results were obtained for EBPF/SP6 (not shown).

Effect of exon 3 and exon 4 acceptor sites on alternative splicing
In silico analysis of the 3' splice sites (3'ss) of the GLB1 gene revealed a low score of 2.5 for the site flanking exon
Different transcripts of the **GLB1** gene. (a) Scheme of the **GLB1** gene. Different possible transcripts are shown. The primers used to amplify these transcripts are indicated by horizontal arrows. Black circles are natural stop codons whereas red circles indicate PTCs. (b) & (c) RT-PCR on cDNA from cycloheximide-treated (CHX) or not treated (NT) HeLa cells and human fibroblasts. The transcripts corresponding to each band are outlined on the right. (b) PCR using C1F/EBPR as primers. (c) PCR using EBPF/C3R as primers. * indicates bands for possible transcripts including only exon 3 or only exon 4.
4, a relatively low score of 6 for the site adjacent to exon 3 and a high score of 10 for exon 6 acceptor site, compared to the average score of constitutive exons (7.9). To check whether the skipping of exons 3 and 4 in the alternative splicing was due to the weak acceptor sites, 2 positions on each 3’ss were mutagenized in the BX minigene, generating the BX3 and BX4 constructs. These changes increased the 3’ss scores on exons 3 and 4, from 6 to 9.5 and from 2.5 to 7, respectively (Figure 2a, b). Analysis of the transcripts generated by these plasmids showed an increase of the transcript including only exon 3 (BX3 lane) and of the transcript including only exon 4 (BX4 lane), although the transcripts lacking both exons were also observed (Figure 3a). Quantification of the transcripts bearing exon 3 (or exon 4) versus transcripts lacking exon 3 (or exon 4), showed small but significant increases. As expected, plasmid BX3 produced proportionally more transcripts bearing exon 3 than BX (116%, Figure 3b), and plasmid BX4 produced more bearing exon 4 (120%, Figure 3c). It should be noted that plasmid BX4 also produced more transcripts bearing exon 3 than BX (124%), but this was not significant. Nevertheless, the fact that some transcripts with skipped exons 3 and/or 4 were still produced, suggests that the weak 3’ splice sites are not sufficient to explain why these exons might be skipped.

Effect of over-expression of SR proteins on alternative splicing

To assess the effect of the SR and hnRNP A/B proteins on GLB1 alternative splicing, HeLa cells were cotransfected with the BX plasmid together with a plasmid expressing one of the following proteins: SF2/ASF, SRp20, SRp40, SRp55, 9G8 or hnRNPA1. The analysis was focused on the inclusion/exclusion of exons 3 and 4. The different transcripts detected by RT-PCR using primers T7/EBP_R were quantified. Although none of these proteins could completely restore the inclusion of one of the exons (3 or 4), important variations in the relative proportion between the different transcripts were detected (Figure 4a–c). The cotransfection of the BX plasmid plus an empty pcDNA3 plasmid was used as a control (BX lane). Quantification of the bands showed that the SR proteins reduced the relative amount of the EBP transcript, compared to the transcript that includes all the exons. Additionally, most of the SR proteins increased the amount of transcripts including exons 3 or 4 (Figure 4b, c). This indicates a function for SR proteins favouring the inclusion of these exons, although

---

Table 1: Primers and RT-PCR conditions

| Primer | Sequence (5’->3’) | GLB1/Exon | Transcript specificity | Pairs of primers employed | AT (°C) |
|--------|------------------|------------|------------------------|---------------------------|--------|
| C1F    | ACTGCAGAGCCGGGAGGCTGTT | 1          | EBP/β-Gal              | C1F/EBPR                  | 58     |
| C3R    | CCAAGTGTACCTTTCATATG | 11         | EBP/β-Gal              | EBPF/C3R                  | 56.5   |
| EBPF   | GGCTGAACGCCATCAGACATT | 2–5        | EBP                    | T7/SP6                    | 55     |
| EBPR   | TGATGTTGCTGCTTCAGCTG | 7–5        | EBP                    | T7/EBPR                   | 56.5   |
| 2_4F   | ACGCCATCCAGACGGAGGAT | 2–4        | NN                     | EBPF/SP6                  | 58     |
| 4_6F   | TCCTCCGACCCAGGTTGAA | 4–6        | NN                     | 2_4F/C3R                  | 59     |
| T7     | TAATACGACTCCTATAGGG | --         | pcDNA3                 | 2_4F/SP6                  | 58.3   |
| SP6    | GATTATGTTGACACTATAG | --         | pcDNA3                 | 4_6F/C3R                  | 59     |
| C1Fm   | GAGACCCCATCTGGCCGCGA | 1          | m EBP/β-Gal            | C1Fm/C1Rm                 | 59     |
| C1Rm   | CTCTAGTGGACCAAGTGTTAG | 4          | m β-Gal                | EBPFm/EBPRm               | 58     |
| EBPFm  | GGGCTGAATGCTATCGAGATAC | 2–5       | m EBP                  |                         |        |
| EBPRm  | TGATGTTGCTGCTGCAGTGGT | 7–5       | m EBP                  |                         |        |

AT: annealing temperature; NN: not naturally occurring; m: mouse.

*GLB1 exon or exons that are complementary to the indicated primers
some seem to favour both exons (SRp40) and others only exon 3 (SRp55 and SF2/ASF) or exon 4 (SRp20 and 9G8). On the other hand, hnRNPA1, which has been reported to inhibit splicing [7], here seems to favour the inclusion of both exons too. However, an in vitro splicing enhancement effect of hnRNPA1 has also been reported [16]. Previous studies have found a close similarity between the RRM's of proteins 9G8 and SRp20, which can recognize some identical sequences [17], and moreover, it has also been reported that 9G8 can participate in splicing regulation as a functional SRp20 homologue in certain conditions [18]. In our study, both proteins produced the same change of pattern (that is, favour the inclusion of exon 4), consistent with these previous results.

To analyse whether the effect of the SR proteins was specific for exons 3 and 4 or if it was a general phenomenon, a similar experiment was performed using the 2_4F/SP6 primers to measure the effect on the inclusion/exclusion of exons 5 and 6 (Figure 5). The results showed again that the SR proteins had a general effect of favouring the inclusion of exons 5 and 6. The experiment was repeated three times with similar results.

The differences in the pattern observed for each protein may indicate their different roles in the constitutive and alternative splicing of these exons. However, it should be taken into account that the over-expression of the SR proteins in the minigene experiments, which is far from being a physiological situation, could alter the interactions between the over-expressed and endogenous SR proteins. Moreover, the characteristics of the minigene, such as the type of promoter or the lack of some of the intronic sequences, should also be considered.

**GLB1 alternative splicing in other species**

It had already been described that the EBP could not be generated in mouse (*Mus musculus*) through the alternative splicing of the GLB1 gene, because the translation of exon 5 in mouse is only possible in the reading frame that codes for lysosomal β-galactosidase [19]. Analysis of the GLB1 exon 5 sequences in different species showed that this also happens in rat (*Rattus norvegicus*). However, in
other mammals such as dog (Canis familiaris), cat (Felis catus), crab-eating macaque (Macaca fascicularis) or rabbit (Oryctolagus cuniculus) and also in birds such as the chicken (Gallus gallus), both reading frames are possible. Therefore, in all the species analyzed in silico, except for rat and mouse, a reading frame where exons 3, 4 and 6 are skipped is possible.

To see if the EBP alternative splicing (i.e. exclusion of exons 3, 4 and 6) occurred in mice, RAW264.7 cells were cultured in the presence and absence of CHX, and β-Gal- and EBP-like-specific RT-PCR were carried out. The C1Fm/ C1Rm primers were used for β-Gal and the C1Fm/EBPRm primers for EBP-like (Table 1). The EBP-like transcript was detected only in the CHX-treated cells (data not shown).

The existence of this EBP-like transcript suggests that its absence in rodents (Murinae) could be explained by the presence of the PTC (a change that is synonymous in the β-gal frame) and the corresponding degradation by NMD.

Figure 3
Semiquantitative RT-PCR on cDNA from transfected HeLa cells with plasmids BX, BX3 and BX4. (a) Semiquantitative RT-PCR using T7/EBPR primers (left) and scheme of the transcript corresponding to each band is shown (right). (b) Percentage of transcripts including exon 3 versus transcripts lacking it, i.e. (1+2)/(3+4). (c) Percentage of transcripts including exon 4 versus transcripts lacking it, i.e. (1+3)/(2+4). Each value is the mean ± S.E. of two independent experiments, each of which was replicated three times. * when p < 0.05.
RT-PCR using primers T7/EBPR after cotransfection with the BX and SR plasmids. (a) Semiquantitative RT-PCR, using primers T7/EBPR, on cDNA from HeLa cells cotransfected with the BX plasmid together with a plasmid expressing one of the following proteins: SF2/ASF, SRp20, SRp40, SRp55, 9G8 and hnRNPA1. The BX lane is the control. The transcripts corresponding to each band are drawn on the right. (b) & (c) Quantification of radio-labelled RT-PCR for the different transcripts (b for transcripts including exon 3 versus transcripts lacking it, i.e. \((1+2)/(3+4)\) and c for transcripts including exon 4 versus transcripts lacking it, i.e. \((1+3)/(2+4)\)), considering BX transfection as 100% in each case. Each value is the mean ± S.E. of two independent experiments, each of which was replicated three times. * when \(p < 0.05\).
The question of which is the gene coding for the mouse EBP protein, if it exists, or which protein performs a similar function, remains open.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
RS performed the experiments. LV and DG designed the experiments and supervised the work. RS, LV and DG wrote the paper. All authors read and approved the final manuscript.

Additional material

Additional file 1
Methods. The file contains a detail description on vector construction, cell culture and transfection conditions, and molecular biology techniques used in this work.

Click here for file: [http://www.biomedcentral.com/content-supplementary/1756-0500-1-137-S1.doc](http://www.biomedcentral.com/content-supplementary/1756-0500-1-137-S1.doc)

Acknowledgements
We would like to thank Alberto R. Kornblitth and Matias Blaustein for advice, for critical reading of the MS and for providing the SR plasmids. We also thank Amparo Chabás for her permanent support to our research on lysosomal diseases. We are also grateful to Mónica Cozar for technical support and to Robin Rycroft for revising the English. RS was the recipient of a fellowship from the Spanish Ministerio de Educación y Cultura. Financial support was provided by CICYT (SAF2006-12276), AGAUR and CIBERER (INTRA/07/720.1). The CIBER de Enfermedades Raras is an initiative of the ISCIII.

References
1. Berget SM, Moore C, Sharp PA: Spliced segments at the 5’ terminus of adenovirus 2 late mRNA. Proc Natl Acad Sci USA 1977, 74(8):3171-3175.
2. Chow LT, Gelinas RE, Broker TR, Roberts RJ: An amazing sequence arrangement at the 5’ ends of adenovirus 2 messenger RNA. Cell 1977, 12(1):1-8.
3. Modrek B, Lee C: A genomic view of alternative splicing. Nat Genet 2002, 30(1):13-19.
4. Roberts GC, Smith CW: Alternative splicing: combinatorial output from the genome. Curr Opin Chem Biol 2002, 6(3):375-383.
5. Cartegni L, Chew SL, Krainer AR: Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 2002, 3(4):285-298.
6. Graveley BR: Sorting out the complexity of SR protein functions. Rna 2000, 6(9):1197-1211.
7. Zhu J, Mayeda A, Krainer AR: Exon identity established through differential antagonism between exonic splicing silencer-bound hnRNP A1 and enhancer-bound SR proteins. Mol Cell 2001, 8(6):1351-1361.
8. Caceres JF, Kornblitth, AR: Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 2002, 18(4):186-193.
9. Mendell JT, Sharifi NA, Meyers JL, Martinez-Murillo F, Dietz HC: Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise. Nat Genet 2004, 36(10):1073-1078.
10. Lewis BP, Green RE, Brenner SE: Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proc Natl Acad Sci USA 2003, 100(1):189-192.
11. Oshima A, Ichik Naga, Y, Sakuraba H, Suzuki Y: Beta-galactosidase-deficient human fibroblasts: uptake and processing of the exogenous precursor enzyme expressed by stable transformant COS cells. Hum Genet 1990, 85(3):305-308.
12. Morreau H, Galjart NJ, Gillemans N, Willemsen R, Horst GT van der, d’Azzo A: Alternative splicing of beta-galactosidase mRNA generates the classic lysosomal enzyme and a beta-galactosidase-related protein. J Biol Chem 1989, 264(34):20655-20663.
13. Privitera S, Prody CA, Callahan JW, Hinke A: The 67-kDa enzymatically inactive alternatively spliced variant of beta-galactosidase is identical to the elastin/laminin-binding protein. J Biol Chem 1998, 273(11):6319-6326.
14. Caciotti A, Donati MA, Boneh A, d’Azzo A, Federico A, Parini R, Antuzzi D, Bardelli T, Nosil D, Kimonis V, et al.: Role of beta-galactosidase and elastin binding protein in lysosomal and nonlysosomal complex of patients with GM1-gangliosidosis. Hum Genet 2005, 25(3):285-292.
15. Morrone A, Bardelli T, Donati MA, Giorgi M, D’Azzo A: Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proc Natl Acad Sci USA 2003, 100(1):189-192.
16. Martinez-Conteras R, Fisette JF, Nasim FU, Madden R, Cordeau M, Chabot B: Intronic binding sites for hnRNP A/B and hnRNP F/
H proteins stimulate pre-mRNA splicing. PLoS Biol 2006, 4(2):e21.

17. Cavaloc Y, Bourgeois CF, Kister L, Stevenin J: The splicing factors 9G8 and SRp20 transactivate splicing through different and specific enhancers. Rna 1999, 5(3):468-483.

18. Lynch KW, Maniatis T: Assembly of specific SR protein complexes on distinct regulatory elements of the Drosophila doublesex splicing enhancer. Genes Dev 1996, 10(16):2089-2101.

19. Morreau H, Bonten E, Zhou XY, D'Azzo A: Organization of the gene encoding human lysosomal beta-galactosidase. DNA Cell Biol 1991, 10(7):495-504.